Stem cell-like ALDHbrightcellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin

Silibinin reverses drug resistance in human small-cell lung carcinoma cells

(2013) David Sadava et al.   CANCER LETTERS

Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells

(2013) K. Shien et al.   CANCER RESEARCH

Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells

(2013) Sílvia Cufí et al.   FOOD AND CHEMICAL TOXICOLOGY

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients

(2013) Mariacarmela Santarpia et al.   Future Oncology

Chemopreventive and Anti-Cancer Efficacy of Silibinin Against Growth and Progression of Lung Cancer

(2013) Samiha Mateen et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines

(2013) Xiaoju Zhang et al.   PLoS One

Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines

(2013) Ping Wang et al.   PLoS One

Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells

(2013) Z Zhang et al.   Cell Death & Disease

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

(2013) Alejandro Vazquez-Martin et al.   Scientific Reports

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo

(2013) Sílvia Cufí et al.   Scientific Reports

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

(2012) Ayodele Ayoola et al.   CANCER INVESTIGATION

Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446

(2012) Xiaofei Qiu et al.   CANCER LETTERS

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

(2012) Cheng-Po Huang et al.   CANCER LETTERS

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

(2012) Toshio Kubo et al.   CANCER SCIENCE

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison

(2012) Wei-Xiang Qi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer

(2012) Asuka Nakata et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

(2012) Tudor Ciuleanu et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma

(2012) Yun-Yong Park et al.   PLoS One

Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis

(2012) MITSUO SATO et al.   RESPIROLOGY

Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links

(2012) Christina Scheel et al.   SEMINARS IN CANCER BIOLOGY

Network Biology of Tumor Stem-like Cells Identified a Regulatory Role of CBX5 in Lung Cancer

(2012) Yau-Hua Yu et al.   Scientific Reports

Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer

(2012) Fariz Nurwidya et al.   Cancer Research and Treatment

A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT

(2011) J L Bryant et al.   BRITISH JOURNAL OF CANCER

The EMT regulator slug and lung carcinogenesis

(2011) J.-Y. Shih et al.   CARCINOGENESIS

Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform

(2011) Paola Marcato et al.   CELL CYCLE

Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

(2011) Antonio Passaro et al.   Expert Review of Anticancer Therapy

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma

(2011) Dong Liang et al.   MEDICAL ONCOLOGY

Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer

(2011) Gouji Toyokawa et al.   Molecular Cancer

Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating–cancer stem cells: distinct, overlapping or same populations

(2011) S Floor et al.   ONCOGENE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

(2010) Tzu-Hua Chang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Predictive biomarkers in the management of EGFR mutant lung cancer

(2010) Rafael Rosell et al.   Annals of the New York Academy of Sciences

Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer

(2010) C D Salcido et al.   BRITISH JOURNAL OF CANCER

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

(2010) Yan Xu et al.   CANCER BIOLOGY & THERAPY

Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling

(2010) J. P. Sullivan et al.   CANCER RESEARCH

Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells

(2010) Gaoliang Ouyang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain

(2010) Rafael Rosell et al.   Clinical & Translational Oncology

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance

(2010) Zhiwei Wang et al.   DRUG RESISTANCE UPDATES

Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer

(2010) Junko Kikuchi et al.   LUNG CANCER

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

(2010) Jin-Haeng Chung et al.   LUNG CANCER

Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation

(2010) J. K. Rho et al.   MOLECULAR CANCER THERAPEUTICS

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication

(2009) Shinji Fujioka et al.   LUNG CANCER

Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer

(2009) F. Jiang et al.   MOLECULAR CANCER RESEARCH

E2f1–3 switch from activators in progenitor cells to repressors in differentiating cells

(2009) Jean-Leon Chong et al.   NATURE

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells

(2008) B. C. Fuchs et al.   CANCER RESEARCH

Aldehyde dehydrogenase activity as a functional marker for lung cancer

(2008) Deniz Ucar et al.   CHEMICO-BIOLOGICAL INTERACTIONS

ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells

(2008) Jan S Moreb et al.   Molecular Cancer

ALDH1A1 and ALDH3A1 expression in lung cancers: Correlation with histologic type and potential precursors

(2007) Miten Patel et al.   LUNG CANCER